What are the clotting factors and which coagulation pathway (extrinsic, intrinsic, or common) does each factor belong to?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clotting Factors and Their Coagulation Pathways

The coagulation cascade consists of three pathways—intrinsic, extrinsic, and common—with specific clotting factors assigned to each pathway based on their activation sequence and functional role.

Pathway Classification

Intrinsic Pathway (Contact Activation Pathway)

The intrinsic pathway is triggered by contact with negatively charged surfaces (such as glass or exposed collagen) and includes:

  • Factor XII (Hageman factor) - Activated by contact with negatively charged surfaces to Factor XIIa 1
  • Factor XI - Activated by Factor XIIa to Factor XIa 2, 3
  • Factor IX (Christmas factor) - Activated by Factor XIa to Factor IXa 2, 3
  • Factor VIII (Antihemophilic factor) - Serves as a cofactor; combines with Factor IXa to form the intrinsic tenase complex 1

The intrinsic pathway amplifies coagulation but is not essential for physiological hemostasis, as evidenced by the fact that Factor XII deficiency does not cause excessive bleeding 2, 4.

Extrinsic Pathway (Tissue Factor Pathway)

The extrinsic pathway is the primary initiator of physiological coagulation, triggered by vascular injury and tissue damage:

  • Factor VII (Proconvertin) - Binds to tissue factor (TF) and is activated to Factor VIIa, forming the extrinsic tenase complex 1, 2
  • Tissue Factor (TF/Factor III) - A transmembrane receptor protein that acts as the cofactor for Factor VII 1, 2, 3

The TF-Factor VIIa complex initiates coagulation by activating both Factor X (leading to the common pathway) and Factor IX (cross-activating the intrinsic pathway) 2, 5.

Common Pathway (Final Common Pathway)

Both intrinsic and extrinsic pathways converge at Factor X, leading to the final steps of clot formation:

  • Factor X (Stuart-Prower factor) - Activated to Factor Xa by either the extrinsic tenase complex (TF-VIIa) or intrinsic tenase complex (IXa-VIIIa) 1, 2
  • Factor V (Proaccelerin) - Serves as a cofactor; combines with Factor Xa to form the prothrombinase complex 1
  • Factor II (Prothrombin) - Converted to thrombin (Factor IIa) by the prothrombinase complex 1
  • Factor I (Fibrinogen) - Cleaved by thrombin into fibrin monomers, which polymerize to form the fibrin clot 1
  • Factor XIII (Fibrin-stabilizing factor) - Activated by thrombin to Factor XIIIa, which crosslinks fibrin polymers to stabilize the clot 6

Key Mechanistic Points

Calcium ions (Ca²⁺) are essential cofactors for multiple steps in the coagulation cascade, particularly for Factors II, VII, IX, and X, which require Ca²⁺ for binding to negatively charged phospholipid surfaces on platelets and extracellular vesicles 1.

The intrinsic tenase complex (Factor IXa-VIIIa) activates Factor X at a rate 50 times higher than the extrinsic tenase complex, providing massive amplification of thrombin generation during the propagation phase 5.

Thrombin plays a central amplification role by not only converting fibrinogen to fibrin but also activating Factors V, VIII, XI, and XIII, as well as platelets, creating a positive feedback loop 1, 2, 5.

Clinical Caveat

The traditional separation into "intrinsic" and "extrinsic" pathways is somewhat artificial—in vivo, tissue factor initiates coagulation through both pathways simultaneously 2, 7. The extrinsic pathway provides initial activation, while the intrinsic pathway (particularly Factor XI) amplifies and propagates thrombin generation. This understanding has led to the development of Factor XI and XII inhibitors as potentially safer anticoagulants, since these factors contribute more to pathological thrombosis than to physiological hemostasis 8, 4, 9.

References

Research

Factor XI and XII inhibitors-Dawn of a new era.

Indian heart journal, 2025

Research

Back to basics: the coagulation pathway.

Blood research, 2024

Guideline

factor xiii: recommended terms and abbreviations.

Journal of Thrombosis and Haemostasis, 2007

Research

Should We Replace the Terms Intrinsic and Extrinsic Coagulation Pathways With Tissue Factor Pathway?

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2017

Research

The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Hematology/oncology clinics of North America, 2016

Research

Factor XI: structure, function and therapeutic inhibition.

Journal of thrombosis and thrombolysis, 2024

Related Questions

What is a visually appealing way to understand the intrinsic, extrinsic, and common coagulation cascades?
What is the clinical significance of the blood coagulation pathway and its management?
What is the initial step in a coagulation workup?
What is the coagulation cascade?
What coagulation parameters should be monitored during labor, particularly those related to the intrinsic and extrinsic coagulation pathways?
What are the treatment considerations for prescribing tamoxifen (20 mg orally daily for five years) in adult patients with estrogen‑receptor‑positive breast cancer, including contraindications, required baseline assessments, monitoring, drug interactions, and alternative endocrine therapies?
Can lisdexamfetamine (Vyvanse) be added to a 23-year-old male with ADHD, PTSD, and anxiety who is currently taking bupropion (Wellbutrin)?
What steps should a 40-year-old Black woman who does not drink alcohol or smoke take to lower insulin and cortisol levels and reduce stubborn upper‑body and abdominal fat?
How do I calculate the FIB‑4 (Fibrosis‑4) score using a patient's age, AST, ALT, and platelet count?
What is the appropriate management of hyponatremia in a patient undergoing FOLFOX (folinic acid, fluorouracil, and oxaliplatin) chemotherapy?
How should I manage a patient with severe anemia (hemoglobin 2 g/dL), pancytopenia, schistocytes on peripheral smear, elevated lactate dehydrogenase, markedly low vitamin B12, normal iron studies, and negative direct and indirect Coombs tests?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.